ConforMIS Inc (NASDAQ:CFMS) major shareholder Archon Capital Management Llc sold 151,022 shares of ConforMIS stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $3.76, for a total value of $567,842.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Archon Capital Management Llc also recently made the following trade(s):

  • On Tuesday, July 9th, Archon Capital Management Llc sold 279,293 shares of ConforMIS stock. The stock was sold at an average price of $3.77, for a total value of $1,052,934.61.

NASDAQ CFMS opened at $3.67 on Friday. ConforMIS Inc has a one year low of $0.36 and a one year high of $4.83. The stock has a 50-day simple moving average of $4.00. The company has a market cap of $253.13 million, a P/E ratio of -4.96 and a beta of 2.30. The company has a debt-to-equity ratio of 0.64, a current ratio of 3.00 and a quick ratio of 2.33.

ConforMIS (NASDAQ:CFMS) last released its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). ConforMIS had a negative return on equity of 97.85% and a negative net margin of 42.90%. The company had revenue of $20.64 million during the quarter, compared to the consensus estimate of $20.11 million. On average, equities research analysts anticipate that ConforMIS Inc will post -0.43 EPS for the current year.

Several equities research analysts recently commented on CFMS shares. Oppenheimer reduced their price objective on Littelfuse from $215.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 2nd. BTIG Research lifted their price objective on Yum! Brands to $114.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. BidaskClub downgraded Xperi from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 19th. Finally, ValuEngine upgraded Vistra Energy from a “hold” rating to a “buy” rating in a report on Wednesday, July 3rd. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. ConforMIS presently has an average rating of “Buy” and a consensus price target of $3.40.

Several institutional investors have recently added to or reduced their stakes in CFMS. Acadian Asset Management LLC grew its stake in shares of ConforMIS by 26.0% during the 4th quarter. Acadian Asset Management LLC now owns 127,166 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 26,202 shares during the period. Larson Financial Group LLC grew its stake in shares of ConforMIS by 588.6% during the 1st quarter. Larson Financial Group LLC now owns 24,100 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 20,600 shares during the period. Cornerstone Advisory LLC bought a new stake in shares of ConforMIS during the 1st quarter valued at about $72,000. CAPROCK Group Inc. grew its stake in shares of ConforMIS by 300.0% during the 1st quarter. CAPROCK Group Inc. now owns 80,000 shares of the medical instruments supplier’s stock valued at $230,000 after purchasing an additional 60,000 shares during the period. Finally, Creative Planning grew its stake in shares of ConforMIS by 133.8% during the 1st quarter. Creative Planning now owns 116,922 shares of the medical instruments supplier’s stock valued at $337,000 after purchasing an additional 66,922 shares during the period. Institutional investors and hedge funds own 34.11% of the company’s stock.

About ConforMIS

Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.

Further Reading: What Are Cryptocurrencies?

Insider Buying and Selling by Quarter for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.